Changes in Soluble CD18 in Murine Autoimmune Arthritis and Rheumatoid Arthritis Reflect Disease Establishment and Treatment Response by Kragstrup, Tue Wenzel et al.
Syddansk Universitet
Changes in Soluble CD18 in Murine Autoimmune Arthritis and Rheumatoid Arthritis
Reflect Disease Establishment and Treatment Response
Kragstrup, Tue Wenzel; Jalilian, Babak; Keller, Kresten Krarup; Zhang, Xianwei; Laustsen,
Julie Kristine; Stengaard-Pedersen, Kristian; Hetland, Merete Lund; Hørslev-Petersen, Kim;
Junker, Peter; Østergaard, Mikkel; Hauge, Ellen-Margrethe; Hvid, Malene; Vorup-Jensen,
Thomas; Deleuran, Bent
Published in:
P L o S One
DOI:
10.1371/journal.pone.0148486
Publication date:
2016
Document version
Publisher's PDF, also known as Version of record
Document license
CC BY
Citation for pulished version (APA):
Kragstrup, T. W., Jalilian, B., Keller, K. K., Zhang, X., Laustsen, J. K., Stengaard-Pedersen, K., ... Deleuran, B.
(2016). Changes in Soluble CD18 in Murine Autoimmune Arthritis and Rheumatoid Arthritis Reflect Disease
Establishment and Treatment Response. P L o S One, 11(2), [e0148486]. DOI: 10.1371/journal.pone.0148486
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            • Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            • You may not further distribute the material or use it for any profit-making activity or commercial gain
            • You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 09. Sep. 2018
RESEARCH ARTICLE
Changes in Soluble CD18 in Murine
Autoimmune Arthritis and Rheumatoid
Arthritis Reflect Disease Establishment and
Treatment Response
TueWenzel Kragstrup1,2*, Babak Jalilian1, Kresten Krarup Keller2, Xianwei Zhang1, Julie
Kristine Laustsen1, Kristian Stengaard-Pedersen2, Merete Lund Hetland3,4, Kim Hørslev-
Petersen5, Peter Junker6, MikkelØstergaard3,4, Ellen-Margrethe Hauge2,7, Malene Hvid1,7,
Thomas Vorup-Jensen1, Bent Deleuran1,2,7
1 Department of Biomedicine, Aarhus University, Aarhus, Denmark, 2 Department of Rheumatology, Aarhus
University Hospital, Aarhus, Denmark, 3 Copenhagen Center for Arthritis Research, Rigshospitalet,
Glostrup, Denmark, 4 Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark,
5 University of Southern Denmark, Odense, Denmark, 6 Odense University Hospital, Odense, Denmark,
7 Department of Clinical Medicine, Aarhus University, Aarhus, Denmark
* kragstrup@biomed.au.dk
Abstract
Introduction
In rheumatoid arthritis (RA) immune activation and presence of autoantibodies may precede
clinical onset of disease, and joint destruction can progress despite remission. However,
the underlying temporal changes of such immune system abnormalities in the inflammatory
response during treat-to-target strategies remain poorly understood. We have previously
reported low levels of the soluble form of CD18 (sCD18) in plasma from patients with
chronic RA and spondyloarthritis. Here, we study the changes of sCD18 before and during
treatment of early RA and following arthritis induction in murine models of rheumatoid
arthritis.
Methods
The level of sCD18 was analyzed with a time-resolved immunoflourometric assay in 1)
plasma from early treatment naïve RA patients during a treat-to-target strategy (the OPERA
cohort), 2) plasma from chronic RA patients, 3) serum from SKG and CIA mice following
arthritis induction, and 4) supernatants from synovial fluid mononuclear cells (SFMCs) and
peripheral blood mononuclear cells (PBMCs) from 6 RA patients cultured with TNFα or
adalimumab.
Results
Plasma levels of sCD18 were decreased in chronic RA patients compared with early RA
patients and in early RA patients compared with healthy controls. After 12 months of
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treatment the levels in early RA patients were similar to healthy controls. This normalization
of plasma sCD18 levels was more pronounced in patients with very early disease who
achieved an early ACR response. Plasma sCD18 levels were associated with radiographic
progression. Correspondingly, the serum level of sCD18 was decreased in SKGmice 6
weeks after arthritis induction compared with healthy littermates. The sCD18 levels in both
SKG and CIA mice exhibited a biphasic course after arthritis induction with an initial
increase above baseline followed by a decline. Shedding of CD18 from RA SFMC and RA
PBMC cultures was increased by TNFα and decreased by adalimumab.
Conclusions
The plasma sCD18 levels were altered in patients with RA, in mice with autoimmune arthri-
tis and in cell cultures treated with TNFα and adalimumab. Decreased levels of plasma
sCD18 could reflect autoimmunity in transition from early to chronic disease and normaliza-
tion in response to treatment could reflect autoimmunity in remission.
Introduction
Rheumatoid arthritis (RA) is characterized by swollen and painful joints caused by immune
system abnormalities [1]. However, seropositivity for autoantibodies like rheumatoid factor
and anti-citrullinated protein antibodies may precede clinical onset of disease [2], and joint
damage can progress despite clinical remission [3]. This indicates, that immune system activa-
tion may be present in preclinical RA and in RA in clinical remission. Therefore, early and
aggressive suppression of synovitis and overactive immune system pathways are principal
goals in current treat-to-target strategies [4]. However, not much is known about the temporal
course of immune system activation during disease development and immune system resetting
during treatment.
The inflammatory response includes many different components. The family of β2 (CD18)
integrins (comprising LFA-1 (CD11a/CD18), complement receptor 3 (CD11b/CD18 or Mac-
1), complement receptor 4 (CD11c/CD18 or p150,95), and CD11d/CD18) is central in the
inflammatory response and in RA. E.g., LFA-1 permits leukocytes to bind ICAM-1 and migrate
to inflammatory foci [5]. Blocking this interaction between β2 integrins and their ligands ame-
liorates arthritis in both animal models of RA and RA [6–10]. β2 integrin small molecule antag-
onists are under evaluation for the treatment of other autoimmune diseases.[11] We and
others have demonstrated a soluble form of CD18 (sCD18) resulting from sheddase activity
[12–18]. Shedding of CD18 is increased during chemotaxis and following stimulation with
TNFα [12,16,17], and the sCD18 complexes compete with the cell-expressed CD18 integrins
for binding to ICAM-1 [12,19]. The plasma concentration of sCD18 seems to be a result of a
balance between production by shedding and depletion by ligand binding, and plasma sCD18
may function as a regulatory factor by limiting leukocyte adhesion. In chronic RA and chronic
spondyloarthritis, the plasma levels of sCD18 are decreased and associate inversely with disease
activity [12,19].
Here, we study changes in plasma sCD18 levels (1) in patients with early RA before and dur-
ing a treat-to-target strategy (patients from the OPERA cohort), (2) in chronic RA patients, (3)
following arthritis induction in murine models of rheumatoid arthritis (the SKG and CIA
Soluble CD18 in RA
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Abbreviations: ACR, American College of
Rheumatology improvement score; CCP, cyclic
citrullinated peptide; CD, cluster of differentiation;
CIA, collagen-induced arthritis; CRP, C-reactive
protein; DAS, disease activity score; EDTA,
ethylenediamine tetraacetic acid; FCS, fetal calf
serum; HAQ, health assessment questionnaire; HC,
healthy control; ICAM-1, intercellular adhesion
molecule 1; Ig, immunoglobulin; IQR, interquartile
range; LFA-1, lymphocyte function-associated
antigen 1; Mac-1, macrophage-1 antigen; OPERA,
OPtimized treatment algorithm in Early Rheumatoid
Arthritis; PBMC, peripheral blood mononuclear cell;
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rheumatoid arthritis; RF, rheumatoid factor; S,
soluble; SFMC, synovial fluid mononuclear cell; TBS,
tris buffered saline; TNFα, tumor necrosis factor
alpha; TRIFMA, time-resolved immunfluorometric
assay; UT, untreated.
models) and (4) in RA synovial fluid mononuclear cell (SFMC) and peripheral blood mononu-
clear cell (PBMC) cultures.
Methods
Patients and healthy controls
Serial plasma samples were obtained from RA patients participating in the OPtimized treat-
ment algorithm in Early RA (OPERA) study (n = 152) (Table 1). The 152 patients used in this
study were randomly selected among the 180 patients included in the trial. Detailed study
design and outcome measures have been published elsewhere [20,21]. Briefly, the patients were
treatment naïve early RA patients with median disease duration before diagnosis of 84 days
(IQR 43–132 days). Upon inclusion the patients were randomized to a step-up methotrexate
protocol in combination with either adalimumab (Humira, Abbvie, Illinois, USA) or placebo.
Patients in either treatment arm received intra-articular glucocorticoid injections when pre-
senting with synovitis as assessed clinically. In this study, we used plasma samples from the
initiation of treatment (0 months) and after 3, 6, and 12 months of treatment. Clinical assess-
ments were obtained at baseline (0 months) and after 3, 6, 12, and 24 months of treatment.
Conventional radiographs of hands and forefeet were scored according to the Sharp/van der
Heijde method at baseline (0 months) and after 6, 12, and 24 months (Table 1). The
Table 1. Characteristics of the early treatment naïve RA patients.
Early RA patients (n = 152)
0 months 3 months 6 months 12 months 24 months
Age (years) 56 (43–63) - - - -
Gender (% female) 69 - - - -
Baseline characteristics
Disease duration (days) 84 (43–130) - - - -
RF (% positive) 71 - - - -
Anti-CCP (% positive) 65 - - - -
Treatment (% placebo) 50 - - - -
Disease activity
CRP (mg/L) 15 (7–40) 7 (7–11) 7 (7–10) 7 (7–8) 7 (7–7)
Patient global (1–100) 67 (42–83) 10 (3–29) 14 (3–41) 15 (2–30) 10 (2–29)
Physician global (1–100) 56 (43–73) 4 (0–12) 4 (0–11) 2 (0–11) 2 (0–5)
HAQ (0–3) 1.1 (0.8–1.8) 0.1 (0–0.6) 0.1 (0–0.6) 0.1 (0–0.5) 0.1 (0–0.5)
DAS28CRP (0–10) 5.6 (4.9–6.3) 2.2 (1.8–3.1) 2.4 (1.8–3.0) 2.0 (1.8–2.8) 2.0 (1.8–2.7)
ACR response (% responders)
ACR20 - 88 85 86 84
ACR50 - 69 73 75 75
ACR70 - 54 57 59 59
ACR90 - 32 25 34 32
Radiographic progression (% progressors)
TSS - - 32 41 48
Erosions - - 27 32 37
JSN - - 20 23 31
Data are expressed as median with IQR. Months indicate time after inclusion (treatment initiation). RF, rheumatoid factor. Anti-CCP, anti-cyclic citrullinated
peptide antibody. CRP, C-reactive protein. HAQ, health assessment questionnaire. DAS28CRP, disease activity score 28 based on C-reactive protein.
ACR, American College of Rheumatology improvement score. TSS, total Sharp score. JSN, joint space narrowing.
doi:10.1371/journal.pone.0148486.t001
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intraobserver intraclass correlation coefficient for total Sharp score (TSS) change was 0.88
(95% CI 0.72 to 0.95).
Plasma from patients with chronic RA was obtained from another study population
(n = 30). At the time of inclusion, patients presented with disease flare with at least one swollen
joint. Median age was 58.5 years (IQR 44.8–66.3 years) and the percentage of females was
66.7%.No disease activity or prognosis scores or test results were available. A subgroup of this
population was randomly selected for use in PBMC and SFMC culture stimulation and inhibi-
tion experiments (n = 6).
Plasma was also collected from age- and gender-matched healthy controls (HCs) from the
Donor Bank at Aarhus University Hospital (n = 88). Median age was 53 years (IQR 46–61
years) and the percentage of females was 68%. All plasma samples were collected in EDTA
tubes and kept at -80°C until use. PBMC and SFMC were isolated by conventional Ficoll-
Paque (GE Healthcare) density-gradient centrifugation and cryopreserved at -135°C until time
of analysis.
SKGmice
Serum samples from a total of 45 SKG mice were included from a previous study [22]. Detailed
description of animals and arthritis induction has been described previously [22,23]. Briefly,
female 11- to 12-week-old SKG mice were equally randomized into five groups with nine mice
in each group. Three groups of animals had arthritis induced by intraperitoneal injection of 20
mg mannan (M7504, Sigma-Aldrich, USA), the animals in another group had arthritis induced
with intraperitoneal injection of 2 mg zymosan A (Z4250, Sigma-Aldrich USA), and the ani-
mals in the last group served as age-matched controls. The arthritis was scored as described by
Sakaguchi et al by an observer blinded for group distribution [24]. After 14, 28, and 42 days the
mice were anesthetized by inhalation with isoflorane (IsoFlo vet, Abbott Laboratories Ltd.
Kent, UK), serum was collected from the orbital sinus, and the mice were sacrificed by cervical
dislocation.
CIA mice
Longitudinal serum samples from a total of 4 female C57BL/6 mice with CIA were included.
Mice were 11–12 weeks of age (Taconic, Ry, Denmark) and kept in Scantainers under SPF con-
ditions (21–25°C, 30–60% humidity and 12-hour light/dark cycle). For development of CIA,
the mice were immunized with chick collagen II and Complete Freund’s Adjuvant at baseline
and after 21 days. Arthritis scores were done in accordance with previously described methods
[25]. After 56 days the mice were sacrificed.
PBMC and SFMC in vitro cultures
SFMC and PBMC were thawed and cultured in culture medium (RPMI medium supplemented
with 10% (v/v) FCS, penicillin, streptomycin, and glutamine) at a density of 2×106 cells/ml.
Cells were grown in either medium alone or medium supplemented with either TNFα at 40
ng/ml (300-01A, Peprotech) or adalimumab at 5 μg/ml (Humira) for 48 h at 37°C in a humidi-
fied incubator 5% (v/v) CO2 without changing of medium. After incubation, supernatants were
stored at -80°C for later sCD18 analysis.
Measuring human sCD18
The concentration of sCD18 in human plasma and culture supernatants was carried out with a
time resolved immunofluorescence assay (TRIFMA) as described previously [12,26]. In brief,
Soluble CD18 in RA
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microtiter plates were coated with KIM185 capture antibody (hybridoma cell line CRL-2839,
GenScript). Following incubation with plasma diluted 1:10 or supernatants diluted 1:2 the
detection of sCD18 was achieved by incubation with biotinylated KIM127 (hybridoma cell line
CRL-2838, GenScript) and Eu3+-conjugated streptavidin and read in a fluorescence plate
reader. A human plasma sample defined to contain 1,000 mU/ml was used to make a standard
curve and two internal controls were used to correct for interassay variations. Buffers contained
bovine and human immunoglobulins to block interference from anti-antibodies such as rheu-
matoid factor in the patient samples [19,26]. Also, signals were read in plates coated with iso-
type mouse IgG1 monoclonal antibody (M7894, Sigma-Aldrich) with no known reactivity as a
negative control.
Measuring mouse sCD18
The measurement of sCD18 concentration in mouse serum was carried out with a TRIFMA as
described previously [18]. Briefly, microtiter plates were coated with a rat anti-mouse CD18
IgG2a capture antibody (clone 313903) at a concentration of 1 μg/ml in PBS pH 7.4 at 4°C
overnight. Samples were diluted 1:10 in TBS/Tween/azid assay buffer containing 1 mM CaCl2,
1 mMMgCl2, and 100 μg/ml heat aggregated human IgG, 100 μg/ml bovine IgG 100 μg/ml rat
IgG, and 100 μg/ml mouse IgG and added to the plates. After incubating the plates overnight at
4°C and following three washes with TBS/Tween/azide, a biotinylated rat anti-mouse CD18
detection antibody (clone C71/16) was added at a concentration of 1 μg/ml in TBS/Tween/azid
assay buffer with 1 mM CaCl2 and 1 mMMgCl2 for 1 hour at room temperature. Following
three washes, signal was developed by incubation with Eu3+-conjugated streptavidin in TBS/
Tween with 25 μM EDTA for 1h at room temperature and read in a fluorescence plate reader.
A mouse serum sample defined to contain 1,000 mU/ml was used to make a standard curve.
Also, signals were read in plates coated with isotype rat IgG2a monoclonal antibody (11021D,
BD biosciences) as a negative control.
Ethics
All human samples were obtained after informed written consent according to the Declaration
of Helsinki. The Danish Data Protection Agency and the Ethics Committee at Region Midt
approved the OPERA study (20070008)[20] and the collection of synovial fluid and peripheral
blood from chronic RA patients for isolation of plasma, SFMCs and PBMCs (20121329).
The Danish Animal Experiment Inspectorate under the Danish Ministry of Environment
and Food approved both the study using SKGmice (2007/561-1317) and the experimental pro-
tocol using CIA mice (2009/561-1667).
Statistics
Patient characteristics were described by the median and interquartile range (IQR). Compari-
sons of the plasma sCD18 levels between groups of unpaired samples were made using the t-
test on log-transformed data. Comparisons of the plasma sCD18 levels between groups of
paired samples were made with the paired t-test on log-transformed data. Comparisons of
changes in plasma sCD18 levels between ACR non-responders and responders were made
using the t-test. Correlation analyses between sCD18 levels and patient clinical scores and test
results were performed with the Spearman correlation. Comparisons of the mouse serum
sCD18 levels between groups of unpaired samples were made using the t-test on log-trans-
formed data. Cell culture experiments were analyzed with nonparametric statistics. Thus, the
Mann-Whitney U test was used for unpaired comparisons and the Wilcoxon signed rank test
was used for paired data. A two-tailed p-value below 0.05 was considered significant.
Soluble CD18 in RA
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Calculations and graphs were made with Stata version 11.1 (StataCorp, College Station, USA)
and GraphPad Prism version 5 (GraphPad Software, San Diego, CA).
Results
The plasma levels of sCD18 were decreased in established RA and
exhibited a biphasic course during a treat-to-target strategy
Plasma samples from early RA, chronic RA patients and HCs were used to establish differences
depending on disease duration. Plasma samples from patients with early RA before and during
a treat-to-target treatment strategy (samples from the OPERA cohort) were used to describe
longitudinal changes in systemic sCD18 levels. The levels of sCD18 in plasma from patients
with chronic RA were significantly lower than in plasma from both early RA patients and HCs
(both P<0.0001). Although the levels of sCD18 in plasma from early RA patients were signifi-
cantly lower than in plasma from HCs (P<0.05) a clear overlap was seen between the two
groups (Fig 1A). The sCD18 levels exhibited a biphasic course during a treat-to-target strategy
with an initial decline (P<0.05) followed by a gradual increase to HC levels (P<0.005)
(Fig 1B).
The increase in plasma sCD18 levels was greater in patients with very
early disease rapidly achieving an ACR response
We further analyzed associations between the changes in sCD18 levels and disease duration
and clinical treatment response in the early RA patients. The increase in plasma sCD18 levels
from baseline to 12 months of treatment was inversely associated with disease duration (ρ =
0.19, P<0.05) (Fig 1C). Further, patients achieving an ACR20, ACR70, and ACR90 response
after 3 months had a greater increase in plasma sCD18 levels in the subsequent time period
from 3 to 12 months of treatment (all P<0.05) (Fig 1D). Thus, ACR20 non-responders had no
increase in plasma sCD18 levels (mean ratio 1.05 (95% CI 0.909–1.20)) while ACR90 respond-
ers had the greatest increase in plasma sCD18 levels (mean ratio 1.34 (95% CI 1.20–1.48)). The
changes in plasma sCD18 level did not differ between patients randomized to methotrexate in
combination with adalimumab and patients receiving methotrexate in combination with pla-
cebo (S1 Fig).
The plasma levels of sCD18 associated inversely with joint space
narrowing
Based on the measurements made above, potential associations were analyzed between the
plasma sCD18 levels and disease activity scores. The levels of plasma sCD18 after 3, 6 and 12
months of treatment were associated with progression in radiographic joint space narrowing
after 12 months (Table 2), and the change in plasma sCD18 during the first 12 months of treat-
ment tended to correlate with radiographic progression the subsequent 12 months (S1 Table).
There were no significant associations between either baseline plasma sCD18 levels or changes
in plasma sCD18 levels and age, gender, RF positivity, anti-CCP positivity, patient global, phy-
sician global, HAQ or DAS28CRP (S2 Table).
The serum levels of sCD18 were lower in mice with established
autoimmune arthritis and exhibited a biphasic course during arthritis
development
We used two murine models of rheumatoid arthritis (the SKG model and the CIA model) to
assess the changes in systemic sCD18 levels before and during arthritis induction. The serum
Soluble CD18 in RA
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level of sCD18 showed a biphasic course after arthritis induction with mannan with an initial
increase and a secondary decline and was decreased in SKG mice 42 days after arthritis induc-
tion with zymosan compared with control SKG mice without arthritis (all P<0.05) (Fig 2A).
There was no significant difference between SKG mice 42 days after arthritis induction with
mannan compared with control SKG mice without arthritis. Following the induction of CIA
Fig 1. Plasma levels of sCD18 in 152 early treatment naïve RA (eRA) patients during 12months of treatment, 30 chronic RA (cRA) patients, and 88
healthy controls (HC). (A) Plasma levels of sCD18 in early RA patients at the time of inclusion, in chronic RA patients, and in HCs. Lines indicate median
and whiskers indicate IQR. Data were analyzed using the student’s t-test on log-transformed data. (B) Plasma levels of sCD18 in RA patients during 12
months of treatment. Symbols and lines indicate median and IQR. DAS28CRP score serves as a measure of clinical disease (symbols and lines indicate
median and IQR). Data were analyzed with the paired t-test on log-transformed data. (C) Association between ratio of the change in plasma sCD18 levels
from baseline to 12 months after treatment and disease duration. Data were analyzed using the Spearman correlation. (D) Ratio of the change in plasma
sCD18 levels from 3 to 12 months after treatment in ACR non-responders (NR) and ACR responders (R) after 3 months of treatment. The mean increase in
plasma levels of sCD18 from 3 to 12 months after treatment was greater in ACR responders compared with ACR non-responders. Boxes and error bars
indicate mean and 95%CI. Data were analyzed using the student’s t-test. Months indicate time after inclusion (treatment initiation). * P < 0.05, *** P < 0.001,
and **** P < 0.0001.
doi:10.1371/journal.pone.0148486.g001
Soluble CD18 in RA
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the serum levels of sCD18 showed an initial increase after each injection of collagen with a sec-
ondary decline (P<0.05) (Fig 2B).
The in vitro CD18 shedding was increased by TNFα and decreased by
adalimumab
In vitro cell cultures with SFMC and PBMC from chronic RA patients with disease flare were
used to study the regulation of CD18 shedding from leukocytes. Shedding of CD18 from RA
SFMC and PBMC was increased by adding recombinant human TNFα and decreased by neu-
tralizing TNFα with adalimumab (all P<0.05) (Fig 3A and 3B).
Table 2. Correlations of sCD18 with radiographic progression.
Radiographic progression (Score12 months−ScoreBaseline)
sCD18 TSS JSN Erosions
0 months ρ -0.09 -0.09 -0.06
P 0.27 0.27 0.46
3 months ρ -0.26 -0.28 -0.11
P 0.0030 0.0013 0.23
6 months ρ -0.19 -0.20 -0.12
P 0.026 0.021 0.17
12 months ρ -0.12 -0.18 -0.042
P 0.19 0.034 0.63
Data were analyzed using the Spearman correlation. ρ, Spearman’s rho. Months indicate time after inclusion (treatment initiation). Radiographic
progression is measured as the difference in TSS, total Sharp score. JSN, joint space narrowing.
doi:10.1371/journal.pone.0148486.t002
Fig 2. Serum levels of sCD18 in SKG and CIAmice. (A) The median value of serum sCD18 in healthy SKGmice was lower compared with mice 14 days
after arthritis induction with mannan but higher compared with mice 42 days after arthritis induction with zymosan. n = 9. (B) The median value of serum
sCD18 in CIA mice was increased after each collagen injection followed by a secondary decrease. n = 4. Lines indicate median and whiskers indicate IQR.
Data were analyzed using the student’s t-test on log-transformed data. Arthritis score serves as a measure of clinical disease (symbols and lines indicate the
median and IQR). * P < 0.05.
doi:10.1371/journal.pone.0148486.g002
Soluble CD18 in RA
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Discussion
In early RA, clinical disease characterized by swollen and painful joints is caused by synovitis.
However, presence of autoantibodies may precede the clinical onset of RA by several years, and
joint damage can progress despite clinical remission. In this way, clinical disease can be seen as
the “tip of the iceberg” with immune activation even in patients without symptoms. Therefore,
early and aggressive synovitis suppression has become the principal goal in “treat-to-target”
strategies. However, the temporal changes of immune system abnormalities during disease
development and therapy and their significance remain poorly understood.
In our previous studies, plasma sCD18 levels were decreased in chronic RA and SpA
patients [12,19]. The circulating sCD18 is shed by leukocytes and can bind ICAM-1. Thus, the
plasma concentration of sCD18 is a result of a balance between production by sheddase activity
and depletion by ligand binding. In this way, decreased levels of plasma sCD18 in chronic
arthritis seems to result from insufficient shedding of CD18 from monocytes and binding of
sCD18 to ICAM-1 [19,27,28]. The findings in this study support that changes in systemic
sCD18 accompanying clinical disease occur in biphasic patterns.
The initial phase of arthritis immediately after induction seems to be characterized by
increased sCD18 levels. Thus, there was an initial increase in serum sCD18 levels 14 days after
arthritis induction in the SKG mice. Also, the serum levels of sCD18 increased immediately
after collagen injection in the CIA mice. This initial phase of arthritis induction in SKG and
CIA mice could be simulated in vitro. The pro-inflammatory cytokine TNFα thus increased
the concentration of sCD18 in both SFMC and PBMC cultures.
The later phase of arthritis with established and chronic disease seems to be characterized
by progressively decreasing sCD18 levels. Thus, plasma sCD18 levels were markedly decreased
in chronic RA patients compared with both early RA patients and HCs, while the decrease in
plasma sCD18 levels observed in early RA patients compared with HCs was less pronounced.
Accordingly, in the SKG mice the serum levels of sCD18 were decreased after 42 days and in
the CIA mice the increase in serum levels of sCD18 after collagen injection were followed by a
secondary decrease. This indicates that decreased levels of sCD18 reflect inflammation in tran-
sition from early to chronic disease.
Fig 3. In vitro CD18 shedding from SFMC and PBMC from 6 chronic RA patients with disease flare after stimulation with TNFα or inhibition with
adalimumab (ADA). The concentration of sCD18 from RA SFMC and PBMCwas increased by TNFα and decreased by adalimumab compared with
untreated cultures (UT). n = 6. (A) The concentration of sCD18 measured as mU/ml. (B) The relative change in sCD18 compared with untreated cultures.
Boxes and error bars indicate median and interquartile range. Data were analyzed using non-parametric statistics. * P < 0.05.
doi:10.1371/journal.pone.0148486.g003
Soluble CD18 in RA
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The decreased plasma sCD18 levels in patients with early RA could be normalized during a
treat-to-target strategy showing a biphasic pattern. There was an initial decrease after 3 months
of treatment followed by a gradual increase to HC levels after 12 months of treatment. The ini-
tial phase of treatment could be simulated in vitro. Anti-inflammatory treatment with adalimu-
mab thus decreased the concentration of sCD18 in both SFMC and PBMC cultures. The late
increase in sCD18 was particularly pronounced in patients with very early disease who quickly
achieved an ACR response. This suggests that immune system abnormalities are only restored
in the early phase of disease and after several months of clinical remission. We speculate that
the secondary increase in systemic sCD18 during remission is caused by a slowly adjusted equi-
librium between production and depletion. This is supported by previous studies showing
changes in monocyte subsets and suppression of endothelial cell activity during treatment of
RA [19,27,28].
Our findings support that changes in systemic sCD18 accompanying clinical disease could
be important for future radiographic progression in early RA patients. The plasma levels of
sCD18 were only associated with JSN and not bone erosions. This is surprising as the two pro-
cesses are often connected. However, the two radiographic measures are not always coupled as
demonstrated by the protective effect of the anti-receptor activator of nuclear factorκB ligand
denosumab on bone erosion and not JSN.[29] JSN is thus believed to be caused by the degrada-
tion of surface cartilage by matrix metalloproteinases from fibroblast like synovial cells and
myeloid cells rather than osteoclasts. In this way, infiltration of myeloid cells could be the link
between low sCD18 plasma levels resulting in low ICAM-1 buffer capacity and progression of
JSN.
Notably the biphasic changes in systemic sCD18 accompanying clinical disease occur with
latency. Thus, there is an unmet need for markers that can guide withdrawal of anti-TNFα
treatment in patients with RA [30]. Using normalization of plasma sCD18 as a marker of
immune system restoration could potentially be helpful. Thus, this would enable anti-TNFα
withdrawal at the time of immune system remission and not just guided by longstanding clini-
cal remission. However, further studies are needed to elucidate whether sCD18 has a role as a
marker of immunological changes.
It is also possible that a recombinant form of sCD18 could be used as a drug to inhibit
inflammation in RA. Currently, there are no available drugs targeting the interaction between
β2 integrins and their ligands. The monoclonal antibody against ICAM-1 (enlimumab) could
not be administered repeatedly because of its mouse origin.[31], and the monoclonal antibody
blocking LFA-1 (efalizumab) had serious side effects due to its strong immunosuppressive
actions [32]. In this context, sCD18 appear to be a possible inhibitor because it is found in both
health and disease and does not block interaction completely. Investigations with LFA-1 small-
molecule antagonists (e.g. BMS-688521) or endogenous antagonists (e.g. Del-1) to treat auto-
immune disease are ongoing [33–35].
One shortcoming of the animal data is that they do not necessarily reflect human disease.
We used SKG and CIA mice because we did not have plasma samples from the RA patients
before they developed clinical disease. The SKG and CIA mouse models seem to be feasible for
studying immune system alterations before and during arthritis development. The SKG and
collagen-induced arthritis (CIA) mouse model of arthritis share important features with
human RA. SKG mice present with symmetric involvement of small joints, elevated serum lev-
els of pro-inflammatory cytokines, presence of rheumatoid factor and joint destruction [36].
Mouse CIA is characterised by symmetrical joint involvement with synovitis, pannus forma-
tion and cartilage and bone erosion [37]. Another weakness is that the difference in serum
sCD18 levels between SKG mice with arthritis and SKG mice without arthritis only reached
significance when using zymosan as arthritis inducer, despite that there was no difference in
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arthritis score between the mannan and Zymosan groups [22]. Another obvious weakness of
potentially using systemic sCD18 as a marker of immunological changes is the rather small
changes observed.
Conclusion
The plasma sCD18 levels were altered in patients with early RA, in mice with autoimmune
arthritis and in cell cultures treated with TNFα and adalimumab. Although the changes in cir-
culating sCD18 reported here could represent temporal immunological changes during treat-
ment of RA and arthritis induction in animals, the clinical utility of sCD18 as a biomarker of
treatment response and disease progression seems to be limited due to the numerically small
oscillations.
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